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An iron stable isotope comparison between
human erythrocytes and plasma†
Friedhelm von Blanckenburg,*a Marcus Oelze,a Dietmar G. Schmid,b
Kirsten van Zuilen,f Hans-Peter Gschwind,b Alan J. Slade,c Sylvie Stitah,d
Daniel Kaufmanne and Piet Swartb
We present precise iron stable isotope ratios measured by multicollector-ICP mass spectrometry
(MC-ICP-MS) of human red blood cells (erythrocytes) and blood plasma from 12 healthy male adults
taken during a clinical study. The accurate determination of stable isotope ratios in plasma first required
substantial method development work, as minor iron amounts in plasma had to be separated from a
large organic matrix prior to mass-spectrometric analysis to avoid spectroscopic interferences and shifts
in the mass spectrometer’s mass-bias. The 56Fe/54Fe ratio in erythrocytes, expressed as permil diﬀerence
from the ‘‘IRMM-014’’ iron reference standard (d56/54Fe), ranges from 3.1% to 2.2%, a range typical
for male Caucasian adults. The individual subject erythrocyte iron isotope composition can be regarded
as uniform over the 21 days investigated, as variations (0.059 to 0.15%) are mostly within the
analytical precision of reference materials. In plasma, d56/54Fe values measured in two diﬀerent
laboratories range from 3.0% to 2.0%, and are on average 0.24% higher than those in erythrocytes.
However, this diﬀerence is barely resolvable within one standard deviation of the diﬀerences (0.22%).
Taking into account the possible contamination due to hemolysis (iron concentrations are only 0.4 to
2 ppm in plasma compared to approx. 480 ppm in erythrocytes), we model the pure plasma d56/54Fe to
be on average 0.4% higher than that in erythrocytes. Hence, the plasma iron isotope signature lies
between that of the liver and that of erythrocytes. This diﬀerence can be explained by redox processes
involved during cycling of iron between transferrin and ferritin.
Introduction
The stable isotopes of iron bear potential to serve as biomarkers
for metabolic processes in humans.1 The introduction of multi-
collector inductively-coupled-mass spectrometers (MC-ICP-MS)
about 15 years ago (see ref. 2 for a review) has enabled
disclosing this potentially rich reservoir of information on
nutrient uptake paths, processes, and eﬃciencies.3 Concerning
the stable isotopes of iron, it is now well-established that the
human blood and muscle tissue are enriched in the stable
isotope of 54Fe by one to two permil [%] over 56Fe when compared to
the human diet.1,3,4 However, the light iron isotopes are distributed
unevenly – blood was found to contain the lightest composition,
whereas the liver was less enriched in 54Fe.1 This picture was
confirmed by a pig model study5 and by observations in mice
and sheep.6
These observations raise mechanistic questions about the
observed tissue dependent iron isotope fractionation. Mass-
dependent stable isotope fractionation may occur during trans-
port of ions or molecules, or during formation or breaking of
chemical bonds. Nevertheless, isotope fractionation will only
become detectable if the atomic species, diﬀering in their
isotope ratios, are separated in physically distinct compart-
ments. Following these considerations it has been suggested
that the uptake of dissolved iron via the intestinal mucosa is
the most likely site of fractionation. In the case of intestinal
iron absorption, the transfer from the luminal side to the blood
plasma is incomplete; on average only 1 mg of dietary supply of
approx. 10 to 15 mg of ingested iron is absorbed.1,7 In addition,
the uptake of elemental iron requires the reduction of dietary
Fe(III) to Fe(II) that is transported by a divalent metal transporter
(DMT-1) via an intestinal ferric reductase (Dcytb).8 The redox
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processes involve an equilibrium isotope fractionation shifting
the 56Fe/54Fe ratio by approx. 3% to low values in the ferrous
iron as shown by experimental determination9 and ab initio
calculation of isotope fractionation factors.10 Within the intestinal
mucosa, a similar, oxidative process via the ferroxidase hephaestin
is required to convert the absorbed Fe(II) back to Fe(III) for further
distribution via transferrin.8
In this regard, the protein transferrin, bearing two iron
binding sites, and contained mostly in blood plasma, is a key
player.11 After intestinal uptake, freshly absorbed iron is loaded
onto transferrin and transported within the blood plasma to
various organs and tissues. Although only about 0.1% of total
body iron (3 mg) is bound to transferrin, the daily turnover is
significant, where 20 to 25 mg are transported through the
blood plasma each day.7a Most iron is transported into the red
bone marrow for synthesis of hemoglobin and erythrocytes. As
noted previously, the internal distribution of iron within the
human body is subject to further isotopic fractionation.1,5 One
possible explanation for the diﬀerent isotopic compositions of
these iron storage compartments is isotope fractionation during
transport or during iron loading and unloading from transferrin.
The same holds for iron release from transferrin. Upon binding
to the transferrin receptor, the transferrin–receptor complex is
internalized via endocytosis. Should isotope fractionation during
transferrin loading and release be zero, then the iron composition
of erythrocytes should resemble that of plasma. However, trans-
ferrin also transports a substantial amount of iron from other
storage compartments like the liver. Thus, another potential
process entailing fractionation is during iron storage and release
from various tissue depots. Iron is stored as a stable ferrihydrate
complex in ferritin where Fe(II) is oxidized to Fe(III) by ferroxidase
in the ferritin complex.12 It has been shown in humans that the
liver contains iron of which the 56Fe/54Fe ratio is higher than that
of erythrocytes.1,5 If during release from the liver this heavy iron is
not fractionated towards the erythrocytes’ ratio, then transferrin
should contain iron comprising a mixture of that delivered during
hemoglobin synthesis with that delivered from the liver. Hence,
the transferrin’s isotope composition should lie between that of
the liver and that of erythrocytes. To date, only one study has
reported the iron composition of human blood plasma and found
it to be enriched in 56Fe over 54Fe relative to blood, and hence
being of composition closer to liver iron.13
In this study we test these hypotheses by presenting precise
iron stable isotope ratios measured in human erythrocytes and
plasma samples. Blood was sampled over a period of 21 days
from 12 healthy male adults. The study was performed within
the context of a ferrokinetics and uptake study of iron following
administration of oral doses of the compound SBR759, labeled
with the stable isotope 58Fe. The results of the iron uptake study
are presented in a companion paper.14 A challenge for such an
investigation is the determination of accurate, stable iron
isotope ratios in plasma. Plasma iron concentrations are
approx. 0.4 to 2 ppm compared to that of erythrocytes which
can be greater than 400 ppm. Hence, a large organic matrix has
to be separated prior to mass-spectrometric analysis to avoid
spectroscopic interferences and shifts in themass-bias introduced
during measurements by impurities contained in the samples.15
Presenting suitable analytical protocols is therefore the first aim
of this study.
Subjects and study design
Our investigation is part of an open-label study that was undertaken
to determine the ferrokinetics and uptake of iron in healthy
volunteers following administration of oral doses of SBR759, an
investigational drug being developed for the treatment of hyperphos-
phatemia in patients with chronic kidney disease, labeled with a
stable 58Fe isotope, (for additional information, see ref. 14). The
clinical part of the study was performed at Covance Clinical Research
Unit AG (former Swiss Pharma Contract Ltd), Allschwil, Switzerland.
This study was approved by the local ethics committee and
was conducted in accordance with the declaration of Helsinki
(1964 and subsequent revisions) and International Conference
on Harmonization-Good Clinical Practice guidelines. All subjects
gave written informed consent before participating in the study.
Subjects
A total of 12, iron replete (i.e., nonanemic), healthy, nonsmoking,
male volunteers between 18 and 45 years of age were recruited. This
subject population was selected because of their propensity for iron
absorption, noting similarities in absorption of therapeutic iron salts
by patients with chronic kidney disease (CKD) on hemodialysis.
Subjects with (i) hematocrit o41%, (ii) hemoglobin o13.8 or
417.2 g dL1, (iii) serum ferritin o20 or 4320 ng mL1, (iv)
transferrin saturationo20%, (v) reticulocyte count41.5% or plate-
letso100000 mL1, and (vi) history of anemia, hemochromatosis or
other dyscrasia(s), e.g. thalassemia, myelodysplastic syndrome, etc.,
were excluded from the study. The mean age was 34.2  8.8 years,
the mean height was 177  7.0 cm, the mean body weight was
80.1  15.1 kg, and the mean body mass index (BMI) was 25.3 
3.8 kg m2. Each subject participated in a 21-day screening period
(Day-2 to Day-21), a baseline period (Day-1), and a 12 hour dosing
period (Day 1, three administrations of 4 g of [58Fe]SBR759 each)
followed by a 3 week ambulatory period and study completion
on Day 21. Subjects received a total daily dose of 12 g (divided
into 3  4 g) (mean SD, n = 12: 12.47  0.017 g) of [58Fe]SBR759.
Sample collection
Serial blood samples were collected at 0 h (pre-dose; baseline),
6, 12, 16, 22 (Day 1), 26, 34 (Day 2), 106 (Day 5), 250 (Day 11),
322 (Day 14), and 490 h (Day 21) post first dose. In order to
avoid hemolysis during Day 1 and Day 2 when several blood
withdrawals took place, blood samples were collected by inserting
a plastic cannula fixed at the forearm. For blood sampling at Days
5, 11, 14 and 21, a metallic needle (venipuncture) was used for
individual samplings. Blood was collected in special 7.5 mL blood
collection tubes for metal analysis by slow aspiration. The
tubes, which resemble a single-use syringe, contained a small
and specified amount of metal impurities (o 50 ng iron/tube;
S-Monovettes for metal analysis; model# 01.1604.400, Sarstedt,
Germany). These tubes also contained about 4–7 mL of a lithium
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heparin solution corresponding to about 0.1% of the final
blood sample volume. After blood collection the tubes were
inverted gently to mix the contents. Immediately after collection,
five aliquots of whole blood were exactly weighed into pre-labeled
polypropylene cryotubes and stored atr20 1C.
Plasma was obtained from heparinized blood by centrifugation
at 2000  g, at 4 1C for 10 min. Plasma was recovered into
pre-weighed tubes (Monovettes for metal analysis, Sarstedt)
and stored at r20 1C. Plasma samples which displayed
visible signs of hemolysis were excluded from data analysis.
Plasma was prepared from blood at 0 h (pre-dose), 6, 12, 16, 22
and 26 h post first dose.
After sample collection, erythrocyte and plasma samples
were frozen immediately and stored atr20 1C until and after
analysis in the analytical laboratories. Samples were shipped to
analytical laboratories under dry ice to keep them frozen.
Materials and methods
Iron stable isotope measurements by MC-ICP-MS require separation
of pure iron from the samples’ matrix. The separation techniques
used as well as the mass-spectrometric analysis have been described
in detail15 and are not repeated here. However, the decomposition of
blood and plasma samples requiresmicrowave-aided treatment. The
required protocols not described in ref. 15 are reported here in more
detail.
Microwave treatment – blood samples
After thawing, each blood sample was shaken gently to ensure
homogeneity. A volume of approx. 100 mL was pipetted into pre-
weighed microwave treatment vessels. After adding 5 mL of 5 M
HNO3 and 1 mL of H2O2 (30% w/w), microwave treatment was
performed on a CEM Mars 5 microwave system (CEM GmbH,
Kamp-Lintfort, Germany) at 1200 Watts, at 200 1C for 2 hours.
Only after complete sample processing the resulting clear
solutions were transferred into Savillexs Teflon beakers and
evaporated to dryness. The residues were re-dissolved in 3 mL
of 6 M hydrochloric acid and split gravimetrically into two
aliquots. One of these aliquots was used for determining the
total iron content in the whole blood sample by using a
calibrated inductively-coupled optical emission spectroscopy
(ICP-OES) system (Varian Vista PRO CCD Simultaneous at the
Institute for Mineralogy from the Leibniz University Hannover,
Germany). In addition, major elements such as nickel that
potentially interferes with the MC-ICP-MS measurements were
quantified by ICP-OES.
Microwave treatment – plasma samples
As plasma sample amounts (approx. 15 mL) were too large to be
decomposed in a single microwave treatment vessel, each
sample was split into 2 aliquots. To each of these 6 mL of
15MHNO3 and, with a lag time of 10min, 1mL of H2O2 (30%w/w)
was added. The solutions were treated with the microwave system
(heating up to 200 1C for 25 min; kept at 200 1C for 50 min). After
cooling down for 40 min, samples were transferred into 90 mL
Savillex beakers. The samples were dried and re-dissolved in
5 mL of 6 M hydrochloric acid. At this stage an insoluble solid
residue precipitated. The residual solid phase was removed by
centrifugation.
To test whether the insoluble residues were free of iron, a
standard addition experiment was conducted on a plasma test
sample. This sample was split into two aliquots before freeze-
drying. The first aliquot was then split into 6 sub-splits. To each
of these a known amount of CertiPURs iron standard was
added in increasing volumes. To the first aliquot, the additions
were made before freeze-drying. To the second aliquot, the
additions were made after dissolution and separation of the
insoluble residue by centrifugation. The iron amounts found in
both experiments were roughly identical within analytical error,
which ranged from 1 to 7%. Hence no iron from the original
plasma or from the additions was lost into the precipitate.
Given that this step did not result in loss of iron, all plasma
concentration measurements were performed on a 300 mL
aliquot taken from the 6 M hydrochloric acid solution.
Iron separation
Sample aliquots, re-dissolved in 6 M hydrochloric acid, were
loaded onto an ion exchange column containing 1 mL of Dowex
AG 1  8, 200–400 mesh anion exchange resin (Dow Water and
Process Solutions). The amount of iron loaded onto the
Eichrom polypropylene columns (Eichrom Europe Laboratories,
Bruz, France) was precisely determined by ICP-OES so that the
exchange capacity of columns was not exceeded. Iron was
separated from the bulk of the matrix following ref. 15.
For samples containing high initial amounts of transition
metals or organic matrices, iron separated by anion exchange
chromatography may not be entirely matrix-free and requires
further purification. Therefore, all samples were neutralised
with ammonia and subjected to a precipitation step.15 For
plasma samples which in general contain much less iron when
compared to blood, a normal precipitation step15,16 could not
be applied. Instead, plasma samples were co-precipitated after
chromatographic separation by adding 1 mL of a 1000 ppm
aluminum solution into 0.3 M HNO3, which was first pre-
cleaned by anion exchange chromatography to remove traces
of iron. The co-precipitation was achieved by adding NH4OH to
the samples. To achieve maximum iron yields, the solutions
were allowed to equilibrate for 1 hour before centrifugation.
The supernatants were removed and the precipitates were
washed 2-times with Milli-Q H2O, followed again by centrifugation
and finally re-dissolved in 1 mL of 6 M hydrochloric acid. To
remove the aluminum, a second anion exchange chromatography
was necessary, which followed the same procedure as the first one
at the beginning of the iron separation scheme. The eluents were
then dried and dissolved in 5 mL of 0.3 M HNO3.
MC-ICP-MS
Several analytical protocols for the precise determination of
iron stable isotopes are published.15–17 In this study we follow
the method described in ref. 15 with adaptations. The isotope
ratios were determined on a Thermo Finnigan ‘‘Neptune’’
Metallomics Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
4 
Ju
ne
 2
01
4.
 D
ow
nl
oa
de
d 
on
 0
7/
08
/2
01
5 
12
:5
1:
56
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2014 Metallomics, 2014, 6, 2052--2061 | 2055
Multicollector ICP-MS at the Institute for Mineralogy from the
Leibniz University Hannover, Germany.18 Sample solutions
were nebulised and introduced using the Thermo Finnigan
stable introduction system (SIS). This system consists of a
combined cyclonic and Scott-type spray chamber. The baseline
measurements prior to each analyses were performed by taking
a deflected baseline at the start of a sequence. An ‘‘on-peak
zero’’ measurement was done before each sample and a standard
measurement was done on 0.3MHNO3 to subtract the background
signal introduced by the interaction of the sample and the ion
beam with parts of the inlet system and the mass spectrometer
from measured standard and sample signals.
Whereas argides can be resolved from each corresponding
iron isotope due to the high mass resolving power of the MC-ICP-
MS, potential isobaric interferences of 54Cr+ and 58Ni+ on 54Fe+ and
58Fe+, respectively, were minimised by removal of chromium and
nickel using anion exchange chromatography. The purity of the
fractions after anion exchange chromatography was monitored by
ICP-OES. To correct for minor residual interferences, the isotopes
52Cr and 60Ni were measured in parallel with 54Fe, 56Fe, 57Fe and
58Fe. The interference correction for 54Cr on 54Fe and 58Ni on 58Fe
was performed according to ref 15. Briefly, the amount of 54Cr was
calculated from the intensity of 52Cr measured simultaneously and
from the average natural 54Cr/52Cr ratio. The amount of interfering
58Ni was calculated from the average natural 60Ni/58Ni ratio. An
instrumental mass discrimination factor was applied to 52Cr and
58Ni intensities, respectively, which was determined from the
measured 57Fe/56Fe ratio by applying the exponential mass
bias law.
Instrumental mass discrimination induced by the incomplete
removal of the sample matrix or non-reproducible mass-spectro-
metric run conditions potentially introduced a substantial bias into
the resulting isotope ratio measurements. As iron concentrations in
blood plasma are low, and a large organic matrix is present, these
measurements are particularly prone to such bias. For this reason
themeasurement of 18 separated plasma iron samples was repeated
on a similar instrument (Thermo Neptune Plus Multicollector
ICP-MS) based at the GeoForschungsZentrum Potsdam. For
these measurements, ESI Apex-Q desolvating apparatus using a
low flow (aspiration rate of 100 mL min1) PFA self-aspirating
nebuliser was used. The ESI Apex-Q apparatus consists of a
heated cyclonic glass spray chamber coupled with a Peltier
element-cooled glass spiral condenser. The mass spectrometer’s
interface was equipped with Thermo ‘‘Jet’’ cones. This instru-
mental setup, which diﬀers considerably from that used at the
University of Hannover, would detect a potential matrix-induced
mass bias in the form of non-reproducible isotope ratios.
Iron standards for controlling MC-ICP-MS measurements
A commercially available ‘‘IRMM-014’’ iron bracketing reference
standard was used (from EU Institute for Reference Materials
and Measurements, Geel, Belgium).19 Additionally, the ‘‘JM’’
internal iron laboratory standard (Fe Puratronic wire, 99.998%
purity, lot NM36883; Johnson & Matthey, London, UK) was used
for optimizing instrumental run conditions and assessing
instrumental reproducibility. The diﬀerences in Fe isotope
composition between ‘‘JM’’ and ‘‘IRMM-014’’ Fe solutions have
been reported.15,18 In this study, additionally a second internal
laboratory standard ‘‘HanFe’’ was measured against the
‘‘IRMM-014’’ iron standard. Iron isotope data for samples is
only accepted if the iron isotope composition of a known iron
standard measured repeatedly in the same analysis session is
within the uncertainty limits.15 To ensure this in each session,
three to six samples of the internal ‘‘JM’’ and the new internal
‘‘HanFe’’ iron reference standards were measured in most
sessions. For the ‘‘JM’’ reference, the mean values obtained in
96 measurements over 18 sessions agreed with those given in
ref 15 and ‘‘HanFe’’ yielded d56Fe/54Fe values within the range
of 0.28 to 0.30% as measured now by four diﬀerent laboratories20
(ESI,† Table S1).
Iron isotope fractionation due to incomplete recovery
Quantitative recovery and removal of matrix elements during
iron separation and precipitation were controlled by iron
concentration measurements with small aliquots of the samples
before and after each step by ICP-OES. This check is important
because non-quantitative recovery could result in artificial iso-
tope fractionation.21 A 90% recovery limit for iron recovery after
ion exchange separation was set as the acceptance criterion. The
total iron recovery was monitored by ICP-OES. Only in four blood
samples the iron recovery was lower than 90%. One sample was
partially lost and did not allow calculating the iron recovery.
Only in two plasma samples, the iron recovery was lower than
90%. One sample was partially lost and could not be analyzed.
The total procedural iron blanks were measured with mostly less
than 60 ng. This was less than 1% of the processed iron (with a
minimummeasurable Fe content of 6 mg) and was considered to
be insignificant.
Reporting of isotope ratios
All isotope ratios were reported in permil deviations from the
‘‘IRMM-014’’ reference material:
d56Fe
%
¼
56Fe=54Fesample
56Fe=54FeIRMM014
 1
 !
 1000
A similar equation is used for d57Fe and d58Fe when 56Fe is
replaced by 57Fe or 58Fe, respectively.
Results
MC-ICP-MS method validation and assessment
Iron isotope specificity and isobaric interferences. To avoid
artefacts introduced by high chromium or nickel corrections,
Fe isotope analyses with 54Cr/54Fe 4 0.1% shall be rejected
from the data set as well as d58Fe values of samples with
58Ni/58Fe 4 10%.15 The interferences on 58Fe are reported in
some detail here as they are important for the companion
paper.14 In this study, the 54Cr/54Fe ratios in blood ranged
from 0.0018% to 0.029% and the 58Ni/58Fe ratios ranged from
zero to 6.20%. The 54Cr/54Fe ratios in plasma ranged from
0.022% to 0.128% and the 58Ni/58Fe ratios ranged from zero to
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9.09%. Two blood samples displayed high 58Ni/58Fe ratios of
18.1%, 34.7%, and one plasma sample showed a 58Ni/58Fe ratio
of 12.9%. Since their measured d58Fe values were suﬃciently
high after absorption of SBR759, these samples were therefore
nonetheless included in the iron absorption calculation.14
Another test for the presence of isobaric interferences is the
use of three isotope plots, where oﬀsets from the predicted
mass-dependent fractionation curve indicate the presence of
isobaric interferences. The delta/delta graphs of normalised
iron isotope ratios (d57Fe/54Fe versus d56Fe/54Fe and d58Fe/54Fe
versus d56Fe/54Fe) of the ‘‘JM’’ and ‘‘HanFe’’ iron standards are
depicted in Fig. S1a–d (ESI†) and of baseline blood and plasma
samples in Fig. S1e–h (ESI†). All standard and sample results
plot onto the mass-dependent isotope fractionation line, which
indicates measurements that were free of spectral interferences.
Blood and plasma samples post first dose containing absorbed
[58Fe]SBR759-related ironmight contain a relatively higher fraction
of 57Fe (i.e. ‘‘impurity’’ in the 58Fe label), as compared to its natural
abundance. The isotopic composition of [58Fe]SBR759 relative to
the international ‘‘IRMM-014’’ reference material was determined
to be 5.706% 54Fe, 89.552% 56Fe, 2.077% 57Fe, and 2.665% 58Fe,14
which compares to 5.845% 54Fe, 91.754% 56Fe, 2.12% 57Fe, and
0.281% 58Fe for the reference material ‘‘IRMM-014’’.19 Hence in
this study d57Fe and d58Fe for post first dose samples are not used.
For plasma samples, we observed higher 52Cr levels than for
either blood samples or the standard materials. We tested
whether this increase was due to unresolved 40Ar12C interfer-
ences on mass 52. In that case the 54Fe intensities would be
over-corrected for 54Cr. We plotted the d57Fe/56Fe ratio against
d56Fe/54Fe of plasma baseline samples (Fig. 1). The 57Fe/56Fe
ratio is not subject to a Cr interference correction. The fact that all
data plot on the mass-dependent fractionation curve, regardless
of whether they have been corrected for Cr interferences, shows
that Cr corrections did not introduce a bias resulting from
excessive 54Fe corrections.
Instrumental iron isotope mass bias drift. The blood and
plasma samples were also monitored for their instrumental
mass bias drift during measurements. Samples for which the
two directly bracketing standard measurements exceed an
instrumental mass bias drift of 200 ppm on the 56Fe/54Fe
ratio were set as a rejection criterion.15 As plasma samples were
diﬃcult to measure due to their complex matrix, we relaxed this
criterion slightly to 220 ppm. The mass bias drift for blood
samples ranged between 202 ppm and 162 ppm (mean  SD
of the absolute values: 44.9 30.0 ppm (n = 181)). Only one sample
exceeded this bias shift slightly (202 ppm) and was rejected. The
drift in mass bias on the 56Fe/54Fe ratios measured in plasma
samples ranged from 476 ppm to 321 ppm (mean  SD of the
absolute values: 96.8  96.6 ppm, n = 71).
Long term iron concentration and isotope ratio stability of
blood and plasma samples
Mean subject iron concentrations in erythrocytes (as measured
in whole blood samples) ranged between 428 and 497 ppm
(Table 1); mean plasma iron concentrations varied between
0.59 and 1.2 ppm (Table 1). Iron concentrations in erythrocyte
samples taken from individual subjects at diﬀerent intervals
varied by 17 to 38 ppm (2SD over all samples, Table S2,
ESI†). Plasma samples varied by 0.25 to 1.2 ppm (2SD over
all samples, Table 1 and Table S3, ESI†) in their iron concen-
trations. This means that relative variations in plasma iron
concentrations were much larger than those in erythrocytes.
d56Fe in erythrocytes ranges from approx. 3.1 to 2.2%
(Fig. 2), a range typical for male Caucasian adults.3 The 2SD
value of erythrocyte samples taken at diﬀerent intervals from an
individual subject varied between 0.06 and 0.15% (2SD),
which is in most cases indistinguishable from the analytical
precision of laboratory standards (Table 1). Hence, erythrocyte
Fe isotopic compositions can be regarded as uniform over the
21 days investigated (Fig. 2). In plasma samples, d56Fe values
ranged from approx. 3.0 to 2.0% (Fig. 3). The 2SD value of
all plasma samples from an individual subject was mostly
around 0.2%, but varied between 0.09 and 0.49% (2SD,
Table 1). We quantified the attainable reproducibility for
plasma measurements from our inter-laboratory comparison,
which provides the strongest possible quantification of the
most likely source of uncertainty, i.e. mass-spectrometric bias
from uncorrectable matrix eﬀects. For our 16 duplicate mea-
surements d56Fe is on average 0.26% and d57Fe 0.37% lower at
GFZ Potsdam than at the University of Hannover (Table S3,
ESI†). This systematic bias resulted from the entirely diﬀerent
run conditions and places a lower limit on the reproducibility
that is attainable for such complex matrix. Such an eﬀect might
arise, for example, from excess amounts of organic carbon
that were still present in the Fe separates during MC-ICP-MS
analysis. Calculating the 2SD value from the sixteen duplicates,
we obtain for d56Fe 0.28% and for d57Fe 0.39%. We use this
Fig. 1 d57Fe/56Fe versus d56Fe/54Fe diagram as test for excessive 54Cr
interference due to the presence of an 40Ar12C interference on the
monitor isotope 52Cr in plasma baseline samples (taken before adminis-
tration of SBR759 to ensure the absence of a 57Fe contribution from the
spike). The 57Fe/56Fe ratio is not subject to a Cr interference correction.
Open symbols: d56Fe not corrected for ‘‘Cr’’ interference; closed symbols:
d56Fe ratios corrected for interferences. The error ellipse denotes the
correlated 2standard deviation as derived from ‘‘JM’’ standard measure-
ments (Table S1, ESI†). The fact that all data plots on the mass-dependent
fractionation curve shows that Cr corrections did not introduce a bias
resulting from excessive 54Fe corrections.
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reproducibility in the interpretation of the data. The plasma
samples taken at 26 hours of subjects 5101 and 5102, respectively,
yielded d56Fe values that deviated more than 25% from that of all
other plasma samples of these subjects (Table S3, ESI†). We have
no explanation for this deviation, and used instead the repeat
measurement performed at GFZ Potsdam that agreed well with
the other samples from these subjects. Overall, the iron isotopic
composition in plasma was more variable than in erythrocytes.
We attribute this variability to the lower reproducibility of these
measurements.
d56Fe in plasma samples is higher than that in erythrocytes
in 11 out of 12 samples by 0.01 to 0.51% (Fig. 4). Only the
subject 5101 features a d56Fe value in its plasma sample that is
lower than that in erythrocytes by 0.21%. The average diﬀerence
in d56Fe between plasma iron and erythrocyte iron is 0.23%
(Table 1). This diﬀerence is only marginally in excess of the 2SD
value resulting from our inter-laboratory comparison. We there-
fore cannot conclude with certainty that the diﬀerence is real.
We note that after administration of [58Fe]SBR759, 57Fe in
plasma samples is elevated over baseline as the 58Fe spike added
also contains elevated levels of 57Fe (see Table S4, ESI†). 56Fe
however is unaﬀected, and plots of 56Fe/54Fe vs. 58Fe/54Fe do not
yield correlations as would be expected if contamination of 56Fe
by [58Fe]SBR759 would occur. However, plasma samples might
have been aﬀected by hemolysis. We proceed to discuss this
question in comparison to literature data in the next section.
Discussion
Lysis of erythrocytes with liberation of hemoglobin (hemolysis)
may occur in vitro when blood samples are taken and plasma is
prepared. Hemolysis can further occur if the centrifugation
procedure has failed to result in a complete separation between
iron in erythrocytes and iron in plasma. Given the large
concentration diﬀerences (480 ppm versus B1 ppm, respectively)
minor hemolysis could contaminate plasma samples with erythro-
cyte isotope composition. In order to minimize hemolysis during
several consecutive blood withdrawals, blood samples were collected
via a plastic cannula placed in a forearm vein that remained through
sampling 26 hours post last dose. Blood sampling and plasma
preparation were carried out throughout the study by qualified
clinical and laboratory personnel. Study-specific training on blood
sampling, including the recognition andminimization of hemolysis,
was also provided.
As spectrophotometric measurements of hemoglobin levels
in our plasma samples were not done, we evaluate this possi-
bility based on literature data. Our measured plasma iron
concentrations are within known values that range between
0.75 and 1.75 ppm for males4b,22 suggesting that iron in plasma
was not contaminated by erythrocyte iron. We can evaluate the
contribution of iron to plasma from hemoglobin further from
hemoglobin levels quantified in plasma by spectrophotome-
try.23 The hemoglobin levels in plasma reported in that study
range between 0.002 and 0.019 (mean 0.007) w/V%. Using the
iron concentration of hemoglobin (0.35 weight%) typical iron
contamination levels between 0.07 and 0.66 ppm with a mean
of 0.24 ppm can be calculated. Since our samples have been
taken and centrifuged with great care, we adopt the mean
minimum hemoglobin iron contamination level of 0.24 ppm
and assume that all iron in excess of this value is truly plasma
iron. This assumption means that iron concentrations of
uncontaminated plasma are between 0.5 and 1.5 ppm.
To calculate the plasma iron isotope composition despite
the possibility of contamination by erythrocyte hemolysis, we
plotted the diﬀerence in d56Fe between erythrocytes and plasma
against the inverse concentration of iron in plasma (Fig. 5). In
such a diagram, mixtures yield a linear relationship and the
Table 1 Mean and 2SD of d56/54Fe iron in blood and plasma and the diﬀerence between means in each subject
Subject
Blood samples Plasma samples
Diﬀerence
plasma – blood
0–490 hours 0–26 hours 0–26 hours 0–26 hours
Fe conc.
[ppm]
2SD
[ppm]
d56/54Fe
[%]
2SD
[%]
d56/54Fe
[%]
2SD
[%]
Fe conc.
[ppm]
2SD
[ppm]
d56/54Fe
[%]
2SD
[%]
d56/54Fe
[%]
2SD
[%] d56/54Fe [%]
Hannover Potsdam Hann Pots
5101 433 32 2.214 0.059 2.194 0.032 1.01 0.63 2.31 0.45 1.95 — 0.12 0.25
5102 428 22 2.490 0.075 2.470 0.019 0.59 0.25 2.21 0.20 2.33 0.13 0.26 0.15
5103 452 38 2.627 0.079 2.609 0.027 1.21 1.19 2.30 0.23 2.40 — 0.31 0.21
5104 471 19 2.801 0.090 2.785 0.095 0.70 0.48 2.77 0.15 — — 0.01 —
5105 491 26 2.708 0.115 2.730 0.102 0.77 0.97 2.45 0.17 — — 0.28 —
5106 460 17 2.676 0.059 2.686 0.028 0.66 0.36 2.56 0.10 — — 0.13 —
5107 466 25 2.626 0.109 2.648 0.069 0.92 0.64 2.38 0.49 2.58 — 0.26 0.06
5108 443 26 2.640 0.151 2.690 0.048 0.66 0.31 2.29 0.23 2.61 0.11 0.40 0.08
5109 442 28 3.061 0.081 3.070 0.088 0.71 0.59 2.73 0.29 2.95 — 0.34 0.12
5110 495 28 2.642 0.112 2.634 0.112 1.02 0.48 2.53 0.25 — — 0.10 —
5111 497 25 2.904 0.067 2.910 0.090 0.71 0.30 2.58 0.18 2.88 0.17 0.33 0.03
5112 495 28 2.561 0.075 2.573 0.069 0.71 0.35 2.07 0.09 — — 0.51 —
Mean 464 2.663 2.667 0.81 2.43 2.53 0.23 0.13
Min 428 17 3.061 0.059 3.070 0.019 0.59 0.25 2.77 0.09 2.95 0.11 0.12 0.03
Max 497 38 2.214 0.151 2.194 0.112 1.21 1.19 2.07 0.49 1.95 0.17 0.51 0.25
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end member compositions can be inferred. The figure shows
that the isotope diﬀerence between Fe in erythrocytes and Fe in
plasma increases with a decrease in the concentration. As
d56Feerythrocytes is constant for each subject this means that
d56Feplasma increases with a decrease in the concentration. This
trend is more pronounced for samples taken from Hours 22 to
26 (open colored symbols) than those taken from Hours 0 to 16
(closed colored symbols). We explain this trend with the
decreasing eﬀect of hemolysis introduced during sampling, as
the inserted plastic cannula remained in place throughout.
Hence the samples taken last approach the true d56Feplasma
most closely.
A linear regression analysis through all our data (Fig. 5)
yields a slope of 0.2 with R2 of 0.2. We used this slope to
model where d56Feerythrocytes – d
56Feplasma would plot if plasma
was contaminated by variable amounts of erythrocytes during
centrifugation (Fig. 5). In this calculation, we assumed the
‘‘pure’’, but unknown plasma iron isotope composition with
three independent models, as shown by the lines and tick
marks in Fig. 5 – in each model the iron concentration in
Fig. 2 d56Fe in erythrocytes of the 12 subjects against sampling time. (A)
All data from Day 1 to Day 21. Note that d56Fe in erythrocytes is invariant
with time over this period. (B) The first 26 hours were sampled at higher
time resolution. The symbols denote individual subjects.
Fig. 3 d56Fe in plasma of the 12 subjects against sampling time. The
symbols denote individual subjects and are the same as in Fig. 2. Error bars
show 2 standard deviations.
Fig. 4 d56Fe in plasma against erythrocytes. Most data plot within 0.5%
within the 1 : 1 line, showing that the individual subjects carry a distinct iron
isotope composition that is similar between erythrocytes and plasma. The
symbols denote individual subjects and are the same as in Fig. 2. The inset
shows results of the inter-laboratory comparison of plasma samples.
Samples measured at Hannover are shown in red and those at GFZ
Potsdam in blue. The plasma samples taken at 24 hours of subjects 5101
and 5102 yielded d56Fe that deviated significantly from all other plasma
samples of these subjects when measured at Hannover. For these samples
the Potsdam data were plotted in the main plot.
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erythrocytes was set to 480 ppm, while the iron concentration in
uncontaminated plasmawas set to 0.4 ppm. For our data the isotope
difference D56Feerythrocytes–plasma obtained to satisfy a slope of 0.2 is
0.4%. We conclude that this value is the average difference
between erythrocyte Fe isotope composition and uncontaminated
plasma isotope composition in our samples.
We can compare this relationship to the one obtained in
ref. 13 Fe in these serum samples13 were on average 1% heavier
than erythrocytes in females and 0.6% heavier in males,
respectively. We note however that while our mean Fe concen-
trations in plasma (0.8 ppm) were similar to the serum data
from ref. 4b (0.9 ppm), Fe concentrations in serum samples of
Albare`de et al.13 were higher with amean concentration of 1.4 ppm.
If the samples in that study were still aﬀected by hemolysis,
modeled slopes demand that their d56Fe in the serum diﬀers by
1.5% from erythrocytes in males, and by 2.5% in females,
respectively, (see D56Fe erythrocytes–plasma models 1.5% and
2.5% in Fig. 5). We regard such strong isotope fractionation as
unlikely. If these experiments were not affected by hemolysis, the
possibility remains that isotope ratios are subject to an unidentified
analytical mass bias. Given the difficult matrix that plasma or
serum represents, and the challenge we have encountered in
developing a suitable analytical protocol, this explanation
cannot be fully excluded.
Using our new plasma data presented here, we proceed with
the conclusion that d56Fe in plasma is at least 0.4% higher than
that in erythrocytes.
Where does the isotope fractionation between plasma Fe
and erythrocyte Fe occur? The liver, spleen, and red bone
marrow contain iron that can be up to 1% heavier than
erythrocytes.1,5 Transferrin is the molecule transporting iron
contained in plasma into and from these compartments. In this
regard, it is important that this study recruited healthy male
subjects who were iron replete i.e. nonanemic and are expected
to have a normal erythrocyte turnover rate. At the end of their
B120 day lifespan, heme iron from erythrocytes in blood,
and myoglobin from the damaged muscle tissue are recycled
after being phagocytosed by circulating macrophages or the
reticuloendothelial system (RES) of the spleen24 and released
back into the plasma bound to transferrin. This recycling rate is
approximately 2 mg per day from erythrocytes and another
2 mg from the muscle tissue,25 potentially dominating the
isotope composition of the iron contained in plasma. As heavy
liver iron is stored in the ferritin molecule, release of iron from
ferritin could play a key role in tissue fractionation since tissues
enriched in heavier iron isotopes are generally high in ferritin
content. In general, two chemical reaction types, binding to
organic molecules and redox processes, lead to diﬀerent
degrees of isotope fractionation. Fe(III) – chelate fractionation
is +0.2% at equilibrium.26 This fractionation factor is too small
to explain the large difference between plasma and liver iron or
erythrocyte iron. Reduction from ferric to ferrous iron through
activity of a reductase is a more likely explanation.6,11 Iron
binding to ferritin involves oxidation of iron via a ferroxidase.27
As noted in the Introduction, these redox processes can be
accompanied by equilibrium isotope fractionation amounting
to up to 3% in d56Fe,9,10 potentially favouring heavy iron
isotopes in ferritin. If transferrin iron remains in the ferric
state, whereas heme iron carried by erythrocytes is in the
ferrous state,1 then plasma iron isotope composition will be
intermediate between that of erythrocyte and ferritin iron, as
the liver will release preferentially heavy iron isotopes, which
are then mixed with light iron isotopes from quantitative
erythrocyte recycling. Hence, redox processes play the decisive
role in iron isotope fractionation between compartments of the
human body, regardless of whether the pathways are direct or
indirect.1,13
Conclusions
A chemical separation procedure using microwave treatment
and anion exchange chromatography was developed for analysis
of iron isotopes in human blood plasma by MC-ICP-MS. The
isotope composition of plasma is exceedingly sensitive to hemo-
lysis which may occur during blood sampling and subsequent
centrifugation. Hence, while within analytical precision the iron
isotopic ratios are identical between whole blood and plasma of
12 healthy male Caucasian adults, these results are also compa-
tible with a plasma iron isotope composition that is at least 0.4%
higher in d56Fe than that of erythrocytes. Ferritin is a key player
that can induce isotope fractionation by release and uptake of
iron, mixing isotopically heavier iron from the liver with plasma
Fig. 5 d56Feerythrocytes – d
56Feplasma versus 1/Fe concentration in plasma.
The colored symbols are from this study (subjects as in Fig. 2), where closed
symbols show data for samples taken from 0 to 16 hours and open symbols
for samples taken from 22 to 26 hours. The grey symbols show data from
ref. 13. The lines and tick marks show three mixing models that serve to
predict how data would be aligned if plasma iron were contaminated by
erythrocyte-sourced iron. In each model the iron concentration in erythro-
cytes was set to 480 ppm, while the iron concentration in plasma was set to
0.4 ppm. The true isotope difference D56Fe erythrocytes – plasma was set
to 0.4%, 1.5%, and 2.5% in the three models. The weight% tick marks
on the model curve indicate the weight fraction of total erythrocyte sample
mixed with total plasma by hemolysis (from 0 to 0.5 and 100 weight%).
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while at the same time lighter iron is released from erythrocytes.
Redox processes involved in ferritin binding and unbinding are
the key players.
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